A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer

@article{Ma2013API,
  title={A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer},
  author={Cynthia X. Ma and Vera J. Suman and Matthew Goetz and Paul J Haluska and Timothy Moynihan and Rita Nanda and Olufunmilayo Olopade and Timothy J. Pluard and Zhanfang Guo and Helen Chen and Charles E Erlichman and Matthew N Bainbridge and Gini F. Fleming},
  journal={Breast Cancer Research and Treatment},
  year={2013},
  volume={139},
  pages={145-153}
}
The mammalian target of rapamycin (mTOR) plays a critical role in promoting tumor cell growth and is frequently activated in breast cancer. In preclinical studies, the antitumor activity of mTOR inhibitors is attenuated by feedback up-regulation of AKT mediated in part by Insulin-like growth factor type 1 receptor (IGF-1R). We designed a phase I trial to determine the maximum-tolerated dose (MTD) and pharmacodynamic effects of the IGF-1R antibody Cixutumumab in combination with temsirolimus in… CONTINUE READING

5 Figures & Tables

Connections & Topics

Mentioned Connections BETA
Neoplastic CellIs abnormal cell of diseaseMammary Neoplasms
The mammalian target of rapamycin ( mTOR ) plays a critical role in promoting tumor cell growth and is frequently activated in breast cancer .
All Topics